A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer.
Authors
Steele, NAnthony, A
Saunders, Mark P
Esmarck, B
Ehrnrooth, E
Kristjansen, P
Nihlén, A
Hansen, L
Cassidy, J
Affiliation
CRUK Clinical Trials Unit, Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow G12 0YN, UK. n.steele@nhs.netIssue Date
2012-02-28
Metadata
Show full item recordAbstract
Pre-clinical data indicate enhanced anti-tumour activity when combining recombinant human interleukin-21 (rIL-21), a class 1 cytokine, with cetuximab, a monoclonal antibody, targeting the epidermal growth factor receptor. This phase 1 trial assessed the safety and tolerability of escalating doses of rIL-21 in combination with cetuximab in chemo-naïve patients with stage IV colorectal cancer.Citation
A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer. 2012, 106 (5):793-8 Br J CancerJournal
British Journal of CancerDOI
10.1038/bjc.2011.599PubMed ID
22315057Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/bjc.2011.599